Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Supernus Pharmaceuticals reported strong growth for the first quarter of 2026, with total revenues of $207.7 million, up 39% from $149.8 million a year earlier. Revenues from commercial products, including collaboration revenue from ZURZUVAE, reached $178.4 million, a 26% increase.
Growth was driven by key CNS products: Qelbree net sales rose 20% to $77.9 million, GOCOVRI grew 15% to $35.2 million, ONAPGO generated $8.4 million after launch, and ZURZUVAE collaboration revenue contributed $27.6 million. The company posted a GAAP net loss of $2.3 million (or $0.04 per share), narrowed from $11.8 million, while non-GAAP adjusted operating earnings improved to $28.7 million. Cash, cash equivalents, and current marketable securities increased to $384.2 million as of March 31, 2026. Supernus reiterated its full-year 2026 guidance, including total revenues of $840–$870 million and non-GAAP adjusted operating earnings of $140–$170 million.
Supernus Pharmaceuticals, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 18, 2026 at 10:00 A.M. EDT. Stockholders will vote on electing two directors for three-year terms, an advisory say-on-pay resolution, ratifying KPMG LLP as auditor for 2026, and amending the 2021 Equity Incentive Plan to increase available shares. The record date is April 29, 2026, when 58,039,721 common shares were outstanding, each entitled to one vote. The proxy also details board composition, committee structures, director and executive biographies, ownership of major stockholders and insiders, and Supernus’ executive compensation philosophy emphasizing pay-for-performance and alignment with stockholder interests.
Supernus Pharmaceuticals Inc shows a passive beneficial ownership disclosure by Vanguard Capital Management reporting 2,900,884 shares of Common Stock, representing 5.03% of the class. The filing lists sole voting power of 433,669 shares and sole dispositive power over 2,900,884 shares.
Vanguard Portfolio Management reports beneficial ownership of 3,263,309 shares of Supernus Pharmaceuticals common stock, representing 5.66% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 3,263,309 shares and sole voting power for 24,616 shares. The Schedule 13G is signed by Ashley Grim on 04/29/2026.
Supernus Pharmaceuticals, Inc. filed a current report stating it will release its first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. Management will host a conference call and webcast that day at 4:30 p.m. ET to discuss the results and take questions.
The live webcast and a replay, available for 60 days, will be accessible through the Investor Relations section of the company’s website. The filing also reiterates that Supernus is a biopharmaceutical company focused on treatments for a range of central nervous system diseases, including ADHD, Parkinson’s disease–related conditions, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Supernus Pharmaceuticals, Inc. entered into and completed an asset purchase agreement with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC to acquire all rights to the compound known as NV-5138 or SPN-820, including related intellectual property, inventory, regulatory materials, data, contracts and goodwill.
The purchase price consists of Supernus completing one Phase 2b study and potentially paying up to $350 million in milestone payments tied to specific development, regulatory and commercial achievements, using commercially reasonable efforts to reach those milestones. If Supernus determines after the Phase 2 study that it was not successful, it has no further obligation to pursue milestones or commercialization of the compound.
The agreement includes customary representations, warranties, covenants and indemnification provisions, allows Supernus to offset indemnification losses against unpaid or previously paid milestone amounts, and imposes a five‑year post‑closing non‑competition and non‑solicitation covenant on the restricted parties.
Supernus Pharmaceuticals Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned, representing 0% of common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that caused disaggregated reporting by subsidiaries. The form is signed by Ashley Grim on March 27, 2026.
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported a series of option exercises and share sales. Over March 16–18, 2026, he exercised employee stock options to acquire 107,250 shares of common stock at strike prices between $27.94 and $39.40 per share.
Across the same dates, he sold 107,250 common shares in open-market transactions at weighted-average prices within ranges from $49.34 to $51.15, with details available in the price footnotes. The filing notes that at least one transaction was made under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these transactions, Bhatt directly holds 17,044 Supernus shares.